Abstract | BACKGROUND: OBJECTIVES: METHODS: Sixty patients with moderate to severe seborrheic dermatitis were evaluated in an open non-comparative study. Patients were treated with oral itraconazole, initially 200 mg/day for a week, followed by a maintenance therapy of a single dose of 200 mg every 2 weeks. Four clinical parameters ( erythema, scaling, burning, itching) were assessed using a 0-3 score. Mycological evaluation determined the presence of Malassezia spores in the scales using a direct smear. RESULTS: At the end of the initial treatment significant improvement was reported in three clinical parameters: erythema, scaling, itching. Maintenance therapy led to only slight further improvement. Burning sensation was only mildly improved during the treatment. The quantity of Malassezia spores present in the direct smear decreased throughout the treatment period. No blood test abnormalities were found during the treatment. CONCLUSIONS:
|
Authors | Avner Shemer, Baruch Kaplan, Nir Nathansohn, Marcelo H Grunwald, Boaz Amichai, Henri Trau |
Journal | The Israel Medical Association journal : IMAJ
(Isr Med Assoc J)
Vol. 10
Issue 6
Pg. 417-8
(Jun 2008)
ISSN: 1565-1088 [Print] Israel |
PMID | 18669136
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antifungal Agents
- Itraconazole
|
Topics |
- Adult
- Antifungal Agents
(administration & dosage, therapeutic use)
- Dermatitis, Seborrheic
(drug therapy, microbiology)
- Facial Dermatoses
(drug therapy, microbiology)
- Female
- Humans
- Itraconazole
(administration & dosage, therapeutic use)
- Male
- Severity of Illness Index
- Treatment Outcome
|